Key Takeaways
-
Dental partnership deals generally fall into four structures: private buy-ins, expense-sharing, DSO joint ventures, and equity rolls. Each structure affects when you receive cash, how much equity you keep, and how much control you retain.
-
Headline price and ownership percentage can be less important than the profit-sharing waterfall, buyout formula, valuation method, and clinical autonomy language in the documents.
-
A structured comparison across five dimensions gives you a repeatable way to evaluate any two offers side by side.
-
The post-buy-in growth attribution problem can cause dentists to pay twice for value they help create unless pricing and growth attribution are defined in advance.
-
McLerran & Associates builds side-by-side valuations across private-buyer and DSO paths so owners can compare dental partnership deals with clear, quantified information.
Talk with McLerran & Associates about your current or potential offers.
Four Core Dental Partnership Structures And How They Differ
The table below shows how the four structures differ on two variables that often drive a dentist’s decision: how much equity they keep and when they get paid. Read it left to right to see how each structure trades liquidity for control.
|
Structure |
Equity Retained By Dentist |
Liquidity Timing |
Clinical/Operational Control |
|---|---|---|---|
|
Private buy-in / doctor-to-doctor partnership |
Defined fractional stake (commonly 25–50%, staged to full ownership) |
Cash at close on sold tranche; lowest cash-at-close share (~35%) of the four paths |
Shared governance between co-owners, clinical protocols set by partner-dentists |
|
Expense-sharing agreement |
100% — no equity transferred; dentists share overhead costs only |
No liquidity event; each dentist retains full practice value independently |
Full clinical and business autonomy for each participating dentist |
|
DSO joint venture (JV) |
Founding dentist typically retains majority ownership, with the DSO acquiring a minority stake of roughly 30–49% (some JV-DSO structures place the dentist’s local-entity ownership anywhere from 20% to 60%) |
40–60% cash on sold stake at close, remainder via future distributions or defined liquidity event |
Dentist retains majority ownership and clinical control, DSO manages non-clinical operations |
|
Equity roll / holding-company equity |
Seller retains a minority rollover stake (typically 20–40% of deal value) in the acquiring platform |
60–80% cash at close, rollover equity illiquid until DSO recapitalization or sale, typically 3–7 years |
Dentist operates under employment agreement, DSO controls non-clinical and often scheduling decisions |
Each structure carries a distinct economic consequence. In a private buy-in, the incoming partner purchases a defined stake, commonly in stages, and the two dentists share revenue, overhead, and governance. Cash at close as a share of total deal value runs lower in partnership buy-ins than in any other path. The selling dentist, however, keeps ongoing income during the partner-track period and avoids a full exit. This structure can fit practices where the owner wants continuity, income, and a trusted successor instead of immediate full liquidity.
An expense-sharing agreement can suit dentists who want to reduce overhead while keeping full ownership. Two or more dentists share costs such as rent, staff, and equipment, while each owns and operates their own patient base independently. No equity changes hands, no valuation is required, and each dentist retains 100% of their practice value. The main risk is conflict over shared costs and patient allocation, which should be addressed explicitly in a written cost-sharing agreement before the arrangement begins.
A DSO joint venture functions as a growth vehicle rather than a pure cash-out of existing equity. The DSO contributes capital and management infrastructure, and the founding dentist retains majority ownership and clinical control. JV structures are more common in implant-focused, sleep dentistry, and multi-location growth practices than in standard general-practice settings. They tend to attract owners aged roughly 45–58 who want expansion capital and support while keeping meaningful control.
An equity roll, which often appears in full DSO or private-equity acquisitions, transfers most of the practice to the buyer in exchange for cash at close plus a retained minority stake in the acquiring platform. That retained stake, often called “rollover equity,” remains illiquid until the DSO itself is sold or recapitalized, an event the industry calls the “second bite of the apple.” Rollover equity should be valued as an investment rather than counted like guaranteed cash. Its eventual value depends on the DSO’s performance and whether a future liquidity event occurs.
Discuss which structure best fits your goals and timeline.
Five Dimensions For Comparing Two Dental Partnership Offers
When two offers sit on the table, a simple headline-price comparison can hide large economic differences. The five dimensions below create a consistent way to compare any two offers side by side.
-
Implied valuation. Back into what the offer actually says the practice is worth. Add the cash at close, the risk-adjusted value of any rollover equity, and the present value of any earnout, which is a deferred payment tied to future performance targets. The key point is the total enterprise value the buyer places on the practice and how they calculate it. Getting this wrong means accepting a lower effective price than the headline suggests. The risk is highest when a large earnout depends on targets you will no longer control after closing.
-
Post-partner compensation. Focus on what the dentist actually takes home after the buy-in or affiliation closes. In a private buy-in, the incoming partner’s distributions depend on the profit-sharing formula and overhead allocation. In a DSO deal, compensation typically shifts from owner distributions to an associate salary of roughly 25–30% of collections, compared to an effective owner rate of roughly 35–45% of collections. Ask for the last 3 years of actual partner distributions, not only projections.
-
Control. Clarify who decides on hiring, equipment purchases, scheduling, expansion, and clinical protocols. In a private partnership, governance rules should spell out which decisions require unanimous consent and which either partner can make independently. In a DSO deal, the management services agreement, which defines what the DSO handles versus what the dentist controls, provides the real answer. Review what is reserved exclusively for the licensed dentist in the written agreement and how that works in practice.
-
Buyout formula. The formula, timing, and triggers that determine what the dentist receives at exit can be as important as the buy-in price. One of the most informative tests of any buy-in is whether the buyout formula is symmetric with the buy-in. If you pay for goodwill on the way in and receive only tangible asset value on the way out, the agreement has revealed what the other party believes the goodwill is worth. Apply the buyout formula to a hypothetical departure today and compare that result to what you are paying to enter.
-
Valuation methodology. The method used to value the practice, such as a percentage of gross collections, a multiple of net cash flow, or a multiple of EBITDA, which means earnings before interest, taxes, depreciation, and amortization, anchors every tranche price. Clarify whether the methodology resets at each tranche and, if it does, who bears the risk of growth-driven valuation increases between tranches. This question connects directly to the post-buy-in growth attribution issue in the next section.
Because McLerran & Associates works both the private-buyer and DSO paths in roughly equal measure, the firm can produce a side-by-side valuation that quantifies a practice’s worth in both markets. That analysis helps an owner compare offers with specific numbers rather than rough guesses.
Request a side-by-side valuation for your practice.
The Post-Buy-In Growth Attribution Problem
The post-buy-in growth attribution problem can be one of the most consequential economic traps in a phased buy-in. It affects how much an associate effectively pays for the growth they help create.
Consider a hypothetical general dental practice valued at $900,000 when an associate purchases a 30% stake for $270,000. Over the next 2 years, the associate builds patient relationships, increases production, and grows the practice’s collections. When the time comes to purchase the next tranche, the practice is revalued, and the new valuation reflects the growth the associate helped generate. In the Practice Worth sample dental practice valuation report (Main Street Dental), the practice is revalued to a range of $1,248,000 (4.0× EBITDA) to $1,872,000 (6.0× EBITDA), with a midpoint market value of approximately $1,560,000 (5.0× EBITDA). In the hypothetical example, the associate pays $225,000 for a 25% stake in the revalued practice, based on a reconciled-and-adjusted value of approximately $900,000. The associate has, in effect, paid twice for a portion of the value they helped build.
If a later tranche is priced off a fresh practice valuation, any growth the associate created during the interim can raise the price the incoming partner pays for the next slice. The agreement should therefore define the valuation method for future tranches upfront rather than renegotiating it at each step.
Three contractual protections can address this problem, and all of them work best when negotiated before signing:
-
Fixed-formula tranche pricing. The agreement specifies a fixed formula, such as a percentage of collections at the original valuation date, adjusted only for inflation or a defined index. The associate’s own production then does not inflate the price of later tranches.
-
Growth attribution clauses. The agreement separates baseline practice value from associate-generated growth. The tranche price applies only to the baseline, and production attributable to the incoming partner’s clinical work is excluded.
-
Valuation reset language. If a fresh appraisal is required at each tranche, the agreement states that associate-generated production is excluded from the valuation base and describes how to separate the two.
Buy-in agreements should address the treatment of associate-created growth, since valuation can be distorted if the future value created after the buy-in is not separated from the pre-buy-in baseline. These protections often appear in well-drafted agreements and can mark the difference between a fair phased buy-in and one that systematically shifts value from the incoming partner to the existing owner.
Have your current or proposed buy-in agreement reviewed for growth attribution risk.
Profit-Sharing Architecture And Buy-Sell Triggers
Profit-sharing terms and buy-sell triggers can change the economic comparison between two offers more than any headline number.
Profit-sharing architecture determines how practice income is divided after expenses. The most common structures are:
-
Equal splits. Profit is divided evenly regardless of individual production.
-
Production-based draws. Each partner takes a percentage of their own collections after proportional overhead.
-
Hybrid models. A base salary is tied to production, and remaining profit is distributed according to ownership percentage.
Unequal production with equal profit splits can create tension. The formula should spell out how it handles adjustments, lab costs, hygiene, and new patients, as well as management time, reserves, and payment timing. The waterfall order, meaning who gets paid first, at what threshold, and at what percentage, determines the real economics of the deal. Two offers with identical ownership percentages can produce very different take-home income depending on how the waterfall is structured.
Buy-sell and exit triggers govern what happens when a partner retires, becomes disabled, dies, or wants to exit voluntarily. A pre-determined valuation process inside the buy-sell agreement can dramatically reduce conflict and confusion later. The buyout formula, whether it uses a fixed price, a formula based on collections or EBITDA, or a third-party appraisal, determines what the departing dentist actually receives. Leaving practice valuation undefined in a buy-sell agreement, or using a formula that no longer reflects market reality, can be a common source of litigation. The ADA advises that valuation and transition terms should be established before the associate relationship begins. The same logic applies to funding. A buyout the surviving partner cannot pay is not a real buyout, which is why life insurance for death triggers and disability buyout insurance for disability triggers should be specified in the agreement and put in place while both partners are insurable.
When comparing two offers, apply each offer’s buyout formula to a hypothetical departure and compare the results. A deal that pays full goodwill value on exit differs economically from one that pays only tangible asset value, even when the buy-in prices appear similar.
Have McLerran & Associates model your profit-sharing and buy-sell outcomes.
Clinical Autonomy As An Economic Variable In DSO Partnership Deals
Clinical autonomy in a DSO deal belongs in the same analysis as cash, equity, and earnout. DSO restrictions on scheduling, mandated suppliers, and treatment workflow can affect both income potential and day-to-day practice flexibility, so autonomy clauses function as an economic variable in offer comparisons.
In a well-structured DSO, the dentist retains authority over diagnosis, treatment planning, and material selection, while the DSO’s influence over scheduling pace, production targets, preferred vendor lists, and software platforms can shape the clinical environment even when no one is explicitly dictating treatment. The practical focus falls on whether the contract’s reservations of clinical authority operate in reality.
Three questions help evaluate autonomy terms in any DSO partnership offer:
-
What is explicitly reserved for the licensed dentist in the written management services agreement? Look for specific language covering diagnosis, treatment planning, clinical referrals, prescribing, and supervision of licensed personnel.
-
Who controls scheduling pace, vendor selection, and software platforms? These operational decisions shape daily clinical life and can affect production and income even when treatment planning authority is preserved.
-
What is the dispute process if the dentist disagrees with a DSO operational decision? A clear, documented escalation path offers meaningful protection.
McLerran & Associates vets buyers like investments and has blacklisted DSOs known for poor post-close environments, steering owners toward well-backed, well-run partners with a record of satisfied sellers. That vetting process helps address autonomy concerns before an offer reaches the table.
Ask McLerran & Associates to review autonomy terms in your DSO offer.
Why McLerran & Associates Focuses On Side-By-Side Dental Deal Comparisons
McLerran & Associates is a dental-only sell-side advisor and advocate that never represents the buyer. Over roughly 35 years, the firm has closed approximately 2,000 practice sales, totaling about $2 billion in transaction volume, and has evaluated more than 10,000 practices. The firm’s work splits almost evenly between private-buyer and DSO transactions, which supports genuine side-by-side comparisons. Brokers who work only one path can describe that path but cannot provide a full-market comparison.
Each engagement starts with a CPA-led, diligence-grade EBITDA analysis completed up front so the numbers hold when buyers scrutinize them and deals are less likely to be re-traded at closing. From that foundation, McLerran creates competition by running a structured, auction-style bid process among a vetted pool of qualified buyers. Owners often realize higher prices and stronger terms than they would achieve selling on their own. The firm’s transaction rate runs roughly 85–90%, compared to an industry norm closer to 35–40%.
For owners who have not yet decided whether to sell, the McLerran M&A Summit (October 29–30, 2026) is a dental-only event designed for that decision point. Attendees receive 4 CE credits and a complimentary practice valuation. They can also engage with the firm’s team of former investment bankers, practice-finance lenders, DSO buyers, and CPAs before committing to any path.
The firm’s mandate centers on maximizing the owner’s outcome and finding the right fit, not only the highest bidder. That approach involves controlling the narrative around EBITDA, creating competition among buyers, and steering owners toward partners whose strategy, structure, and support model align with the owner’s goals for the practice after transition.
Explore whether McLerran & Associates is the right advisory fit for your practice.
Frequently Asked Questions
What Is The Difference Between A Private Practice Partnership And A DSO Partnership?
In a private practice partnership, a dentist buys a defined equity stake in an existing practice from another dentist, and the two become co-owners sharing revenue, overhead, and governance. Clinical and business decisions are made by the partner-dentists themselves. In a DSO partnership, a corporate entity acquires some or all of the practice’s non-clinical assets and provides management services under a formal agreement, while the dentist typically continues practicing under an employment or services arrangement. The main differences involve who controls operational decisions, how equity is structured, when liquidity occurs, and what the buyout formula provides at exit. The right choice can depend on practice size, the owner’s goals, and the specific terms of each offer.
What Is An Expense-Sharing Agreement In Dentistry?
An expense-sharing agreement is an arrangement in which two or more dentists work from the same premises and share operating costs such as rent, staff, equipment, and overhead, while each keeps their own income, patient list, and practice value. No equity changes hands and no valuation is required. Each dentist can sell or wind down their own practice independently, subject to the premises arrangement and any notice to the other dentists. The primary risks involve disputes over how shared costs are allocated and how patients are assigned when dentists’ schedules overlap. A written cost-sharing agreement that specifies which expenses are shared, how they are divided, and how disputes are resolved is essential before the arrangement begins.
How Do I Compare Two Dental Partnership Offers?
Compare offers across five dimensions: implied valuation, which reflects what the offer says the practice is worth including earnout and rolled equity; post-partner compensation, which reflects what you take home after the deal closes; control, which covers who decides on hiring, equipment, scheduling, and expansion; buyout formula, which determines what you receive when you exit and whether it mirrors what you paid to enter; and valuation methodology, which describes whether the practice is valued on collections, net cash flow, or EBITDA and whether that method resets on later tranches. Apply each dimension to both offers using the same inputs, and model the after-tax value of each component separately rather than relying on headline numbers. Consulting your own CPA and a dental-specific advisor before making any decision is strongly recommended.
What Terms Matter Most In A Dental Partnership Buy-In?
Several terms can shape the economic outcome. These include the valuation methodology and whether it resets at each tranche, the profit-sharing formula and waterfall order, the buyout formula and whether it mirrors the buy-in, governance rules specifying which decisions require unanimous consent, and provisions addressing associate-created growth in phased buy-ins. The buy-in price itself can be less important than the compensation formula on the other side of it. A higher buy-in price paired with a strong profit-sharing structure can outperform a lower buy-in price with a weak distribution formula. All of these terms should appear in writing before the associate relationship begins.
How Does A Buy-Sell Agreement Affect What I Get When I Exit?
A buy-sell agreement specifies the valuation method, payment timeline, and triggers that govern what a departing partner receives. The buyout formula, whether it uses a fixed price, a collections-based formula, an EBITDA multiple, or a third-party appraisal, determines the actual dollar amount. Trigger events typically include retirement, voluntary departure, disability, death, and dispute. Funding mechanisms, such as life insurance for death triggers and disability buyout insurance for disability triggers, determine whether the remaining partner can pay the buyout when a trigger occurs. A buy-sell agreement that is not funded with appropriate insurance can leave the plan without a practical payment mechanism. The agreement should be reviewed and updated as the practice grows, ownership percentages change, or the partners’ retirement timelines shift.
Should I Get A Valuation Before Comparing Partnership Deals?
A professional valuation can provide the foundation for any meaningful comparison. Without it, you are comparing offers against an unknown baseline and cannot easily evaluate whether a headline price is fair, whether an earnout is reasonable, or whether rolled equity is appropriately sized relative to the practice’s actual worth. A diligence-grade valuation also helps control the narrative when buyers scrutinize the numbers. A weak or informal valuation can be challenged during due diligence, which can lead to downward renegotiation. For owners weighing both a private-buyer and a DSO path, a side-by-side valuation that quantifies the practice’s worth in both markets can support a more informed comparison. Consult your own advisors to determine the appropriate valuation approach for your specific situation.
Conclusion: Turning Dental Partnership Offers Into Clear Choices
What you sign and what you actually receive can diverge sharply. The valuation methodology, profit-sharing waterfall, buyout formula, growth attribution terms, and clinical autonomy provisions largely determine that outcome. Headline price and ownership percentage serve as a starting point for analysis rather than the final answer.
McLerran & Associates is a dental-only sell-side advisor and advocate that works both the private-buyer and DSO paths in roughly equal measure. That balance supports genuine side-by-side comparisons so owners can weigh dental partnership deals with specific, structured information. That track record, built over roughly 35 years and 2,000 practice sales, reflects what can happen when owners enter the process with experienced representation.
Start a confidential conversation about your practice and potential partnership paths.
